COMMUNIQUÉS West-GlobeNewswire

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
31/03/2025
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable [...]
Noom To Streamline Access to Zepbound® Vials with Noom GLP-1 Companion Through Integration with LillyDirect® Pharmacy Provider
31/03/2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced an agreement with Eli Lilly [...]
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
31/03/2025
Policy update increases access for millions covered by Evernorth Health Services MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical [...]
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
31/03/2025
MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
SS Innovations Achieves Significant Milestones in 2024
31/03/2025
The Company’s award winning SSi Mantra surgical robotic system has completed over 3,500 surgeries and is clinically validated to perform more than 100 different types of surgical procedures The Company Continues to [...]
Safety Shot Provides Business Update from CEO Jarrett Boon
31/03/2025
SCOTTSDALE, Ariz., March 31, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company, today provides a business update from CEO Jarrett Boon [...]
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
31/03/2025
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic [...]
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
31/03/2025
Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE [...]
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
31/03/2025
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
LB Pharmaceuticals Presents New Data from Phase 2 Clinical Trial of LB-102 at the 2025 Annual Congress of the Schizophrenia International Research Society
31/03/2025
Treatment with LB-102 resulted in a positive shift in disease severity as measured by mean change from baseline in Clinical Global Impression of Severity (CGI-S) scores Phase 3 clinical trial of LB-102 in acute [...]
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
31/03/2025
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition DOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- [...]
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect [...]
Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System
31/03/2025
Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goals NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or [...]
Opus Genetics Announces Financial Results for Full Year 2024
31/03/2025
Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement $30.3 million [...]
Transactions in connection with share buy-back program
31/03/2025
Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce [...]
Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI
31/03/2025
AGOURA HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic,” the “Company,” or “We”), a leader in RNA-based therapeutics, today announced the publication of its latest [...]
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
31/03/2025
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung [...]
LifeMD to Participate in the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the 24 th Annual Needham Virtual [...]
FluidForm Bio™ Announces Participation in Venture Summit West
31/03/2025
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will deliver a company [...]

Pages